Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Non-Current Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Other Non-Current Assets for 4 consecutive years, with $230000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 90.08% to $230000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $230000.0, a 90.08% increase, with the full-year FY2025 number at $230000.0, up 90.08% from a year prior.
  • Other Non-Current Assets was $230000.0 for Q4 2025 at Day One Biopharmaceuticals, down from $317000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $487000.0 in Q1 2023 to a low of $117000.0 in Q2 2024.
  • A 4-year average of $264187.5 and a median of $222500.0 in 2025 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 195.15% in 2023, then tumbled 65.71% in 2024.
  • Day One Biopharmaceuticals' Other Non-Current Assets stood at $469000.0 in 2022, then tumbled by 54.37% to $214000.0 in 2023, then plummeted by 43.46% to $121000.0 in 2024, then soared by 90.08% to $230000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Other Non-Current Assets are $230000.0 (Q4 2025), $317000.0 (Q3 2025), and $183000.0 (Q2 2025).